Indivior Pharmaceuticals, Inc. Expense Breakdown
No Expense Breakdown for SUPN on this site yet.
- 2026-06-30: Reportable $33.67M.
- 2025-06-30: Reportable $16.83M.
Source checked: the stored Expense Breakdown page for SUPN.
Expenses by product
Cost of sales: each quarter (3 month)
| Quarter end | Reportable |
|---|---|
| 2026-06-30 | $33.67M |
| 2025-06-30 | $16.83M |
General And Administrative Expense: each quarter (3 month)
| Quarter end | Reportable |
|---|---|
| 2026-06-30 | $40.85M |
| 2025-06-30 | $28.42M |
Marketing Expense: each quarter (3 month)
| Quarter end | Reportable |
|---|---|
| 2026-06-30 | $23.88M |
| 2025-06-30 | $20.73M |
Research and development: each quarter (3 month)
| Quarter end | Reportable |
|---|---|
| 2026-06-30 | $29.46M |
| 2025-06-30 | $22.11M |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |